U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT06968572) titled 'Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion' on April 09.
Brief Summary: This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and PD of HSK41959 when given orally in patients with MTAP Deletion locally advanced or metastatic Solid Tumors.
Study Start Date: April 11
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
DRUG: HSK41959
Oral administration, QD
Recruitment Status: RECRUITING
Sponsor: Haisco Pharmaceutical Group Co., Ltd.
Disclaimer: Curated by HT Syndication....